Effect of oral ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever
| Autor: | Esragül Akinci, Ayhan Kubar, Pınar Öngürü, Ayşe Erbay, Selim Sırrı Eren, Nurhayat Bayazit, Hürrem Bodur |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Microbiology (medical) Crimean–Congo hemorrhagic fever medicine.medical_specialty Administration Oral Disease Antiviral Agents Gastroenterology Virus Young Adult chemistry.chemical_compound Internal medicine Ribavirin Humans Medicine Hemorrhagic fever Young adult Aged business.industry Case-control study General Medicine Middle Aged Viral Load medicine.disease Treatment Outcome Infectious Diseases chemistry Case-Control Studies Hemorrhagic Fever Virus Crimean-Congo Immunology Disease Progression Population study Female Hemorrhagic Fever Crimean business Viral load |
| Zdroj: | International Journal of Infectious Diseases. 15:e44-e47 |
| ISSN: | 1201-9712 |
| DOI: | 10.1016/j.ijid.2010.09.009 |
| Popis: | Summary Objectives Crimean-Congo hemorrhagic fever (CCHF) is a lethal hemorrhagic disease. There is currently no specific antiviral therapy for CCHF approved for use in humans. In this study we aimed to investigate the effect of oral ribavirin treatment on the viral load and disease progression in CCHF. Methods The study population was composed of patients who had a definitive diagnosis of CCHF by means of clinical presentation plus detection of viral RNA by reverse transcriptase polymerase chain reaction (RT-PCR). Ten patients who received oral ribavirin for 10 days and 40 control patients who received supportive treatment only were included in the study. Ribavirin treatment consisted of oral ribavirin 4g/day for 4 days and then 2.4g/day for 6 days. Viral load and hematological and biochemical laboratory parameters, which were measured daily, were analyzed. Results Mean age (37.4 vs. 45.5, p =0.285), gender (male 50% vs. 62.5%, p =0.470), days from the appearance of symptoms to admission (4.3 vs.4.4 days, p =0.922), and initial complaints were similar between the ribavirin group and the control group. Upon hospital admission, mean viral load was 8.2×10 8 copies/ml in the ribavirin group and 8.3×10 8 copies/ml in the control group ( p =0.994). During follow-up, no statistically significant differences were found between the groups with regard to the decrease in viral load, the reduction in alanine aminotransferase and aspartate aminotransferase levels, and the increase in platelet count. The case-fatality rate was 20% (2/10 patients) in the ribavirin group and 15% (6/40 patients) in the control group ( p =0.509). Conclusion In this study, oral ribavirin treatment in CCHF patients did not affect viral load or disease progression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|